Linked Life Data

19012503

Source:http://linkedlifedata.com/resource/pubmed/id/19012503

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
12
pubmed:dateCreated
2008-11-17
pubmed:abstractText
Patients with high-risk, relapsed or refractory Hodgkin lymphoma, those with systemic anaplastic large-cell lymphoma, and those with primary cutaneous CD30-positive disorders are in need of novel therapies. CD30, a common marker in these malignancies, is a reasonable immunologic target given its restricted expression in normal states. SGN-30 is a chimeric antibody targeting CD30.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
1744-7658
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
17
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1883-7
pubmed:dateRevised
2011-8-1
pubmed:meshHeading
pubmed:year
2008
pubmed:articleTitle
SGN-30: a basis for the effective treatment of CD30 positive hematopoietic malignancies.
pubmed:affiliation
Clinical Professor of Medicine, Geffen School of Medicine at UCLA, Director, UCLA Lymphoma Program, 10945 Le Conte Avenue, Suite 2333, Los Angeles, CA 90095, USA. lpinterbrown@mednet.ucla.edu
pubmed:publicationType
Journal Article, Review